RHOA and glaucoma: The involvement of RhoA/ROCK signaling in the pathogenesis of glaucoma is well established and led to the discovery of FDA approved Rho kinase inhibitors (RKI) such as ripasudil and netarsudil for glaucoma therapy18,19.